Therapure Biopharma has postponed its IPO citing market conditions.
Piramal has announced its intention to invest $10m (€8.9m) in Coldstream Laboratories, the US sterile injectable CDMO it bought last year.
Discovery services firm Selvita plans a new laboratory in Poland citing a desired to develop the facility as its “second heart.”
CRO Envigo has confirmed that two of its rat strains can catch the virus that causes genital herpes.
Biologics developers backed by Medicxi Ventures’ new €210m ($229m) fund will use Lonza for contract manufacturing under an existing deal with Index Ventures .